San Francisco-based Rodan & Fields, LLC will shell out $38m to settle multiple class actions in US and California state courts concerning the multi-level marketing firm’s Lash Boost conditioning serum and the prostaglandin analogue that powers it.
Prostaglandin Analogues In Eyelash Cosmetics: Rodan & Fields To Settle Litigation For $38M
R&F will establish funds totaling $38m to put the kibosh on claims of fraud and unfair competition in US federal and state class actions, while maintaining it never intended its prostaglandin analogue-containing Lash Boost to impart drug-like structure and/or function effects on the human body. The settlement does not require R&F to stop selling Lash Boost or reformulate the product.
More from United States
• By
Some FDA employees who were recently laid off by the Trump Administration are being called back to work, multiple sources confirmed to the Pink Sheet.
• By
Proposed administrative order likely is first to prompt opposition from OTC industry or other stakeholders potentially delaying or deferring the agency’s expectation for moving its proposal to a deemed final order effective one year after it would be published.
• By
Qnovia notes NRT inhalation product recently received investigational new drug clearance from FDA as agency and NIH say innovation needed smoking cessation to help improve rate of success for quitting the habit that kills around 500,000 US consumers annually.
• By
The Washington State Department of Ecology will try to work with companies that violate the Toxic Free Cosmetics Act, rather than reflexively imposing the $5,000-per-violation fine for first-time offenders, says the law’s implementation planner. She noted financial assistance is available for small businesses, as well as incentives for companies adopting measures “beyond compliance.”